Mangion Sean E, Mackenzie Lorraine, Roberts Michael S, Holmes Amy M
UniSA: Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia; Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South 5011, South Australia, Australia; Sydney Medical School, University of Sydney, Camperdown 2050, New South Wales, Australia.
UniSA: Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia; Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South 5011, South Australia, Australia.
Eur J Pharm Biopharm. 2023 Apr;185:148-164. doi: 10.1016/j.ejpb.2023.01.023. Epub 2023 Feb 25.
Seborrheic dermatitis (SD) is a common dermatological disorder with symptoms that include skin flaking, erythema and pruritus. This review discusses the topical products available for treating SD, which target several aspects of disease pathobiology, including cutaneous microbial dysbiosis (driven by Malassezia yeast), inflammation, sebum production and skin barrier disruption. Among the various treatments available, zinc pyrithione (ZnPT) based products that exhibit anti-fungal action are the market leaders. A skin compartment approach is presented here for combining ZnPT exposure information with threshold levels for anti-fungal efficacy and toxicity, overall providing a comprehensive picture of ZnPT therapeutics and safety. While Malassezia yeast on the surface are effectively targeted, yeast residing beyond the superficial follicle may not receive adequate ZnPT for anti-fungal effect forming the basis for skin re-colonisation. Levels entering systemic circulation from topical delivery are well below toxic thresholds, however the elevated zinc levels within the viable epidermis warrants further investigation. Strategies to improve formulation design can be broadly classified as influencing 1) topical delivery, 2) therapeutic bioactivity, 3) skin mildness, and 4) sensory attributes. Successful SD treatment ultimately requires formulations that can balance efficacy, safety, and consumer appeal.
脂溢性皮炎(SD)是一种常见的皮肤病,症状包括皮肤剥落、红斑和瘙痒。本综述讨论了可用于治疗SD的局部用产品,这些产品针对疾病病理生物学的几个方面,包括皮肤微生物群失调(由马拉色菌酵母驱动)、炎症、皮脂分泌和皮肤屏障破坏。在各种可用的治疗方法中,具有抗真菌作用的吡硫翁锌(ZnPT)基产品是市场领导者。本文提出了一种皮肤区室方法,用于将ZnPT暴露信息与抗真菌疗效和毒性的阈值水平相结合,总体上提供了ZnPT治疗学和安全性的全面情况。虽然表面的马拉色菌酵母能被有效靶向,但位于浅表毛囊之外的酵母可能无法获得足够的ZnPT来产生抗真菌效果,这构成了皮肤重新定植的基础。局部给药进入体循环的水平远低于毒性阈值,然而,活表皮内锌水平的升高值得进一步研究。改善配方设计的策略可大致分为影响1)局部给药、2)治疗生物活性、3)皮肤温和性和4)感官属性。成功的SD治疗最终需要能够平衡疗效、安全性和消费者吸引力的配方。